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of ischemic stroke moderate and severe degrees of severity using a drug cerebroly-
sin compared with standard therapy, cost-effectiveness ratios (CER) were obtained 
419656 RUB (6920 EUR) and 563183 RUB (9287 EUR), respectively. ConClusions: The 
standard therapy in combination with drug cerebrolysin has a lower CER compared 
with standard therapy, therefore, it is a dominant technology from the perspective 
of the cost-effectiveness analysis.
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objeCtives: Diagnostic algorithms to detect undiagnosed patients with rare dis-
eases have the potential to improve patient health and reduce costs associated 
with misdiagnosis. Accurate algorithms are difficult to develop, typically having 
to overcome Challenges including the tendency for models to I) over-fit, arising 
from low degrees of freedom / high-dimensionality and II) under-predict the rare 
disease, arising from the low ratio of confirmed to unconfirmed cases (skewed 
outcome class distribution). Support Vector Machines (SVMs) are a highly successful 
class of machine learning algorithms with well-established methods for handling 
high-dimensionality and skewed outcome class distribution. SVMs therefore rep-
resent a promising method to detect patients with undiagnosed rare diseases. This 
study estimated risk scores for a rare oncology disease using SVMs. The perfor-
mance of the models was compared to classical methods based on logistic regres-
sions. Methods: Risk scores for confirmed diagnosis were estimated with logistic 
regressions (standard, weighted and Firth) and SVMs (regularization, weights and 
kernel parameters were optimized using internal cross-validation). Patients with 
high risk scores and without a confirmed diagnosis have a higher probability of 
being undiagnosed cases. Model development, validation and testing were carried 
out on separate random samples from linked primary and secondary care data in 
the UK (Clinical Practice Research Datalink and Hospital Episode Statistics). The 
key performance metric was maximizing Sensitivity at a Positive Predicted Value 
(PPV) of 10% based on test data. Results: 334 confirmed cases were identified from 
approximately 1 million total cases. For a PPV of 10%, the Sensitivity for the best 
performing logistic regression (standard with no weights) and SVM (RBF kernel) was 
44% and 58% respectively on test data. ConClusions: SVMs represent a promising 
method for detecting undiagnosed patients with rare diseases, out-performing more 
conventional approaches based on logistic regressions. Greater adoption of these 
methods for this purpose is encouraged.
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objeCtives: Many diseases (e.g. oncology) display changing hazard rates over time 
that conventional parametric methods cannot replicate accurately. Various “flexible 
parametric” methods exist with increased number of parameters to alleviate this 
problem (Generalised Gamma and Generalised F distributions being examples). 
Royston-Parmar Hazard Rate Models (RPHRM) differ in one crucial regard – all key 
survival statistics (survival probability, cumulative hazard and hazard rate) can 
be calculated in closed form. This makes them ideal for HE models where speed 
of calculation is essential. It is relatively straight-forward to program such mod-
els in R to represent competing risks, non-proportional hazard ratios, adding RCT 
obtained hazard ratios to observational study standard of care baseline hazard esti-
mates, and extrapolation under various scenarios. All of this is possible under both 
Semi-Markov Cohort and Patient Level Discrete Event Simulation, DES, modelling. 
We display theory and R example code that illustrates these features. Methods: 
Publicly available example datasets were analysed using RPHRM within Stata (ado 
stpm2) under a maximum likelihood framework (Bayesian MCMC methods could 
be programmed). Parameters obtained were entered into various R functions. Key 
functions were those that derived the restricted cubic spline basis (and its deriva-
tive) associated with log time and its interaction with covariates deemed to have 
time varying effects. For DES modelling a Newton-Raphson algorithm was simple 
to program to generate event times. Competing risks were modelled by numeric 
integration (trapezium rule) to generate cumulative incidence functions from cause-
specific hazards using established formula. Results: Models were able to repli-
cate the real features of the inputted data. Output was validated against published 
results. PSA was conducted successfully and quickly. Required R functions were 
relatively short. ConClusions: RPHRM is the most suitable of “flexible parametric” 
survival models for HE modelling. It can represent any baseline hazard and hazard 
ratio time path without requiring time-consuming calculations.
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objeCtives: Rheumatoid arthritis (RA) is a chronic autoimmune disease that 
causes pain, stiffness and limited motion and function of joints. There are several 
biomarkers (HAQ,VAS,DAS28) known for measuring disease activity from different 
point of views. The main objective is to investigate the association among them 
based on advanced statistical methods. Methods: Different biomarkers of 489 
RA patients were collected in one of the largest Arthritis Center in Hungary from 
5th Jun 1998 to 27th Feb 2015. Copula models are simple yet powerful tools for 
modeling joint distribution of multivariate variables. There are several parametric 
gain. Microsimulation and Markov cohort models use simpler models with aver-
age annual HAQ progression rates that can differ between treatments. A few of the 
Markov cohort models treat disease progression as separate states of the DAS28 
and estimate transition probabilities between such states over time. Disease pro-
gression of a radiographic score was modelled in one study, assuming a decreased 
deterioration of the radiographic score while being on treatment. No study modeled 
the impact of disease progression models on ACR response criteria. Finally, the two 
reviews did not include any cost-effectiveness analysis using decision trees that 
contained a disease progression model. ConClusions: Health economic decision 
models in RA include disease progression predominantly through the HAQ score. 
The impact of disease progression on discrete outcomes such as ACR20/50/70 is 
rarely considered in health economic models in RA.
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objeCtives: Cost-efficacy analysis (CEA) (e.g., cost per cure or short-term 
response) is increasingly being used as an alternative or a supplement to cost-util-
ity analyses (CUA) employing the incremental cost per quality-adjusted life-year 
(QALY) gained. The objective of this study was to investigate whether conclu-
sions drawn from such CEAs were consistent with those of the gold standard 
CUA. Methods: We developed a model comparing standard of care (SOC) with 
a new drug. At the end of therapy, patients incurred short-term costs and either 
achieved a response or not. Non-responders incurred additional long-term costs 
and lost additional QALYs compared with responders. We evaluated two scenarios. 
In Scenario A: the short-term cost was $40,000 and efficacy was 65% with SOC. 
Drug cost and efficacy were $50,000 and 90%, respectively. For responders, the 
long-term cost offsets were $10,000 and additional QALYs were 0.5. Scenario B 
differed from Scenario A in only two aspects: the drug was more costly ($60,000), 
and the additional QALYs were higher (2.0 QALYs). We computed average cost-
efficacy ratio (ACER), incremental cost-efficacy ratio (ICER), and incremental cost-
utility ratio (ICUR). The assumed threshold for cost-effectiveness was $50,000/
QALY. Results: We found that a lower ACER than SOC was neither necessary 
(Scenario A: $66,667 vs $61,539/responder and ICUR= $35,000/QALY) nor sufficient 
(Scenario B: $55,556 vs $61,539/responder and ICUR= $60,000/QALY) for a more 
efficacious drug to be considered cost effective. Although the drug had a higher 
ICER in Scenario A ($80,000 per additional responder) than Scenario B ($40,000/
responder), the drug was cost-effective in Scenario A, and not so in Scenario B. 
We derived a formula that related ICER to ICUR. ConClusions: A lower average 
or incremental cost-efficacy ratio from a CEA was neither a necessary nor a suf-
ficient condition for a new drug to be considered cost effective compared with 
SOC based on a CUA.
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objeCtives: To demonstrate the limitations of the incremental cost-effectiveness 
ratio (ICER) as a measure of improved cost-effectiveness in the context of periodic 
screening and to propose a new measure based on net benefit that quantifies the 
proportional gain in cost-effectiveness relative to the status quo. Methods: We 
use published cost-effectiveness estimates of cervical cancer screening to show why 
the ICER is not an appropriate measure of improvement in cost-effectiveness when 
screening performance improves, either through enhanced test characteristics or 
better risk stratification. We then propose a new metric based on the net health 
benefit measure previously devised by Stinnett and Mullahy. Results: It is shown 
how an improvement in screening may enhance cost-effectiveness, represented by 
an outward shift of the efficient frontier in the cost-effectiveness plane, but that 
this improvement is not necessarily reflected in the ICER. This is because the whole 
efficient frontier may shift when all strategies are affected by a common technologi-
cal change, and so ICERs on the frontier can be insensitive to this improvement. It 
is also shown that the ratio of costs to effects of a given strategy before and after 
a technological improvement also does not provide a useful measure of improved 
cost-effectiveness. The alternative measure of the proportional increase in net 
health benefit following the adoption of a new technology is then demonstrated. 
This metric quantifies the increase in net health benefit resulting from the new 
technology over a range of threshold values. ConClusions: ICERs will remain 
important for the identification of optimal intervention strategies. However, they are 
not suited for all circumstances. The net benefit alternative proposed here is a sim-
ple quantification of improved cost-effectiveness. The results presented here most 
readily apply to screening interventions, but also have application in other cases in 
which a technological development enhances multiple strategies simultaneously.
PRM129
cost-effectiVeness anaLysis of ceRebRoLysin in the tReatMent of 
Patients With acUte ischeMic stRoke MoDeRate anD seVeRe DegRees 
of seVeRity in the RUssian feDeRation
Kulikov A, Abdrashitova G
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To estimate the cost-effectiveness of neurotrophic and neuroprotec-
tive drug cerebrolysin as treatment for patients with ischemic stroke of moderate 
and severe degrees of severity for one year. Methods: Information retrieval was 
conducted in the public domain. We used the pharmacoeconomic analysis method 
– cost-effectiveness analysis and analysis of the direct and indirect costs. For refer-
ence, we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: In this study 
the life-years gained (LYG) was used as a criterion of the efficiency. During the cost-
effectiveness analysis we have found that the cost of one LYG less for the therapy 
